MedPath

FDA Reconsiders Shortage Listing for Eli Lilly's Tirzepatide

• The FDA is reevaluating the shortage listing for Eli Lilly's tirzepatide, a drug used to treat type 2 diabetes and obesity, potentially improving patient access. • Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, has faced supply constraints due to high demand, impacting availability for patients. • The FDA's decision to reconsider the shortage listing suggests a possible improvement in the supply chain and manufacturing capacity for tirzepatide. • This reassessment could lead to better management of patient needs and reduce the burden on healthcare providers in prescribing alternative treatments.

The FDA is reportedly reconsidering the shortage listing for Eli Lilly's tirzepatide, a medication crucial for managing type 2 diabetes and obesity. This reassessment comes amid ongoing efforts to stabilize the drug's supply chain and meet the escalating patient demand.
Tirzepatide, marketed under the brand names Mounjaro for type 2 diabetes and Zepbound for weight loss, has experienced significant supply constraints since its approval. The high demand has led to challenges in ensuring consistent availability for patients who rely on the medication to manage their conditions effectively.
The potential removal of the shortage listing indicates that Eli Lilly may have made progress in scaling up production and distribution to satisfy market needs. This development could alleviate the pressure on healthcare providers who have had to navigate prescribing alternatives due to the limited availability of tirzepatide.
While the FDA's final decision remains pending, the reconsideration signals a positive step towards resolving the supply issues that have affected patients and the healthcare system. Improved access to tirzepatide would enable more individuals to benefit from its therapeutic effects in controlling blood sugar levels and promoting weight loss, ultimately enhancing patient outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Applied Therapeutics Awaits FDA Decision on Govorestat for Galactosemia

Applied Therapeutics is seeking FDA approval for govorestat, a novel aldose reductase inhibitor, for the treatment of galactosemia, a rare metabolic disorder.
Govorestat aims to reduce the production of galactitol, a toxic metabolite that causes neurological damage in galactosemia patients, with no currently approved therapies.

Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU - MSN

EU Approves Pfizer's Hympavzi for Severe Hemophilia A and B

The European Commission has granted marketing authorization for Hympavzi, a new treatment developed by Pfizer.
Hympavzi is indicated for severe hemophilia A or B in both adult and adolescent patients without inhibitors.

Zepbound Demonstrates Superior Weight Loss Over Wegovy; FDA Actions Advance Lung Cancer and Psoriatic Arthritis Therapies

Eli Lilly's Zepbound showed a 47% greater relative weight loss compared to Novo Nordisk’s Wegovy in a head-to-head obesity study.
Merck's sacituzumab tirumotecan (Sac-TMT) received FDA Breakthrough Therapy designation for advanced NSCLC with EGFR mutations.

Tirzepatide Shows Promise in Phase III Trial for Heart Failure with Preserved Ejection Fraction

Tirzepatide significantly reduced heart failure outcomes risk by 38% compared to placebo in patients with HFpEF and obesity.
The trial also demonstrated a 56% reduction in the risk of hospitalization for heart failure among patients treated with tirzepatide.

FDA Approves Hympavzi (marstacimab-hncq) as Novel Treatment for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq), a novel monoclonal antibody, for hemophilia A and B in patients 12 years and older.
Hympavzi offers a new mechanism by reducing tissue factor pathway inhibitor, enhancing thrombin production to facilitate blood clotting.

FDA Approves Emrosi for Rosacea, Proposes Removal of Oral Phenylephrine

The FDA has approved Journey Medical's Emrosi (minocycline hydrochloride extended-release capsules) for treating inflammatory lesions of rosacea in adults, based on positive Phase 3 trial data.
Clinical trials demonstrated that Emrosi was more effective than both placebo and the current standard treatment, Oracea, in reducing inflammatory lesions associated with rosacea.

FDA to Reassess Tirzepatide Shortage Status Amidst Compounding Dispute

The FDA will re-evaluate the shortage status of tirzepatide, the active ingredient in Zepbound and Mounjaro, following a lawsuit from compounding pharmacies.
A court ruling allows compounders to continue producing tirzepatide medications while the FDA reviews its earlier declaration that the shortage was resolved.

FDA to Reconsider Ban on Compounded Versions of Lilly's Weight Loss Drug

The FDA will reconsider its decision to bar drug compounders from selling versions of Eli Lilly's Zepbound and Mounjaro, following a lawsuit by the Outsourcing Facilities Association.
The agency will allow compounding pharmacies to continue providing compounded tirzepatide while reviewing whether a shortage of the active ingredient exists.

FDA Approves Pfizer's Hympavzi for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq), a once-weekly subcutaneous injection, for hemophilia A and B to prevent or reduce bleeding episodes.
Hympavzi is the first anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B, offering a new mechanism of action.

Reference News

[1]
Recon: FDA may rethink shortage listing for Eli Lilly's tirzepatide - RAPS
raps.org · Oct 14, 2024

FDA may reconsider shortage listing for Eli Lilly's tirzepatide; Pfizer receives FDA approval for injectable Hympavzi fo...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy